Skip to main content

#151474

DR3-/- KO Mouse

Cat. #151474

DR3-/- KO Mouse

Cat. #: 151474

Sub-type: Mouse

Availability: 8-10 weeks

Disease: Progressive neurological disease

Model: Knock-Out

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Eddie Wang ; Mike Owen

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Primary Citation: Wang et al. 2001. Mol Cell Biol. 21(10):3451-61. PMID: 11313471

Tool Details
Handling
Target Details
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: DR3-/- KO Mouse
  • Research fields: Apoptosis and autophagy;Cancer;Cell biology;Cell signaling and signal transduction;Genetics;Immunology
  • Tool sub type: Mouse
  • Disease: Progressive neurological disease
  • Model: Knock-Out
  • Conditional: No
  • Description: The DR3-/- mouse exhibits complete knockout of DR3, a death domain-containing tumour necrosis factor receptor, which mediates one of the key regulators of the cell division cycle. Negative selection and anti-CD3-induced apoptosis are significantly impaired in DR3-null mice. In contrast, both superantigen-induced negative selection and positive selection are normal. The pre-T-cell receptor-mediated checkpoint, which is dependent on TNFR signaling, is also unaffected in DR3-deficient mice. These data reveal a nonredundant in vivo role for this TNF receptor family member in the removal of self-reactive T cells in the thymus. Other behavioral studies on DR3 KO mice indicated that DR3 plays a key nonredundant role in the retention of normal motor control function during aging in mice and implicate DR3 in progressive neurological disease
  • Application: In vivo studies of DR3-induced apoptosis & function; in vivo studies of negative T cell selection and development
  • Genetic background: A DR3 targeting vector, replacing the entire DR3 coding region with a loxP flanked resistance cassette, was transfected into GK129 ES cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. Chimeric offspring were bred with C57BL/6 mice to yield mice heterozygous for the mutant allele.
  • Phenotype: Immune abnormalities (T cell development);
  • Zygosity: Homozygous
  • Production details: A DR3 targeting vector, replacing the entire DR3 coding region with a loxP flanked resistance cassette, was transfected into GK129 ES cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. Chimeric offspring were bred with C57BL/6 mice to yield mice heterozygous for the mutant allele.

Handling

  • Shipping conditions: Dry Ice

Target Details

  • Target: DR3 (Death Domain Receptor 3)
  • Target background: DR3 (Ws1, Apo3, LARD, TRAMP, TNFSFR12) is a member of the death domain-containing tumor necrosis factor receptor (TNFR) superfamily, members of which mediate a variety of developmental events including the regulation of cell proliferation, differentiation, and apoptosis

Application Details

  • Application: In vivo studies of DR3-induced apoptosis & function; in vivo studies of negative T cell selection and development

References

  • Twohig et al. 2010. J Neurosci. 30(10):3782-92. PMID: 20220013
  • Wang et al. 2001. Mol Cell Biol. 21(10):3451-61. PMID: 11313471

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.